Galectin Therapeutics (GALT) Projected to Post Earnings on Tuesday

Key Points

• Galectin Therapeutics (NASDAQ:GALT) is expected to announce its Q2 2025 earnings on August 12th, with analysts predicting a loss of ($0.16) per share.
• The stock recently traded at $3.55, down 1.1%, and has a market capitalization of approximately $224.69 million.
• Bank of America recently increased its stake in Galectin Therapeutics by 101.4% during the fourth quarter, indicating growing institutional interest.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.05. On average, analysts expect Galectin Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Galectin Therapeutics Price Performance

Galectin Therapeutics stock opened at $3.77 on Thursday. The firm has a 50 day simple moving average of $2.39 and a 200-day simple moving average of $1.74. The stock has a market cap of $238.60 million, a price-to-earnings ratio of -5.24 and a beta of 0.82. Galectin Therapeutics has a 1-year low of $0.73 and a 1-year high of $3.90.

Institutional Investors Weigh In On Galectin Therapeutics

An institutional investor recently raised its position in Galectin Therapeutics stock. Bank of America Corp DE grew its holdings in shares of Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) by 101.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,358 shares of the company's stock after purchasing an additional 19,316 shares during the period. Bank of America Corp DE owned about 0.06% of Galectin Therapeutics worth $49,000 as of its most recent SEC filing. Institutional investors and hedge funds own 11.68% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on GALT shares. Wall Street Zen raised Galectin Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, June 21st. HC Wainwright began coverage on shares of Galectin Therapeutics in a research note on Tuesday, June 17th. They set a "buy" rating and a $6.00 target price for the company.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.